TLX fell a more muted 6.6%, outperforming the other four stocks looked at today, as class actions captured headlines: The lawsuit alleges that Telix and certain executives made false or misleading statements, or failed to disclose material information about its business, including the progress of its prostate cancer therapeutic programs and the quality of its supply chain and partners. The only obvious winners here will be the lawyers, because if the lawsuit gets traction, shareholders will be punished further.
This $4bn healthcare giant is also suffering from the high growth rerating washing through the ASX with the RBA now expected to hike rates in 2026.
- We continue to like TLX as a business, having identified a break of $13 as a potential buying opportunity, BUT it’s not for the faint-hearted.
MM likes TLX as an aggressive buy
Add To Hit List
